@article {Erg{\"u}naye202101078, author = {Tunahan Erg{\"u}nay and {\"O}zgecan Ayhan and Arda B Celen and Panagiota Georgiadou and Emre Pekbilir and Yusuf T Abaci and Duygu Yesildag and Mandy Rettel and Ulduz Sobhiafshar and Anna Ogmen and NC Tolga Emre and Umut Sahin}, title = {Sumoylation of Cas9 at lysine 848 regulates protein stability and DNA binding}, volume = {5}, number = {4}, elocation-id = {e202101078}, year = {2022}, doi = {10.26508/lsa.202101078}, publisher = {Life Science Alliance}, abstract = {CRISPR/Cas9 is a popular genome editing technology. Although widely used, little is known about how this prokaryotic system behaves in humans. An unwanted consequence of eukaryotic Cas9 expression is off-target DNA binding leading to mutagenesis. Safer clinical implementation of CRISPR/Cas9 necessitates a finer understanding of the regulatory mechanisms governing Cas9 behavior in humans. Here, we report our discovery of Cas9 sumoylation and ubiquitylation, the first post-translational modifications to be described on this enzyme. We found that the major SUMO2/3 conjugation site on Cas9 is K848, a key positively charged residue in the HNH nuclease domain that is known to interact with target DNA and contribute to off-target DNA binding. Our results suggest that Cas9 ubiquitylation leads to decreased stability via proteasomal degradation. Preventing Cas9 sumoylation through conversion of K848 into arginine or pharmacologic inhibition of cellular sumoylation enhances the enzyme{\textquoteright}s turnover and diminishes guide RNA-directed DNA binding efficacy, suggesting that sumoylation at this site regulates Cas9 stability and DNA binding. More research is needed to fully understand the implications of these modifications for Cas9 specificity.}, URL = {https://www.life-science-alliance.org/content/5/4/e202101078}, eprint = {https://www.life-science-alliance.org/content/5/4/e202101078.full.pdf}, journal = {Life Science Alliance} }